Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population

Sevilla, Jaypee; Klusty, Jessica M.; Song, Younghwan; Russo, Mark J.; Thompson, Christin; Jiao, Xiayu; Clancy, Seth; Bloom, David E.

doi:10.1080/13696998.2022.2112442

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, patients who did not undergo TAVR had 5‐year mortality of 93.6%, which is higher than 10‐year mortality among patients who underwent TAVR in this study 24 . Sevilla et al performed a cost‐utility analysis and cost–benefit analysis for patients who underwent TAVR for symptomatic severe aortic stenosis and concluded that across risk and age groups, TAVR was the economically optimal treatment of choice and TAVR represented strong value‐for‐money per patient population‐wide 25 …”

Section: Discussionmentioning

confidence: 58%

“…24 Sevilla et al performed a cost-utility analysis and cost-benefit analysis for patients who underwent TAVR for symptomatic severe aortic stenosis and concluded that across risk and age groups, TAVR was the economically optimal treatment of choice and TAVR represented strong value-for-money per patient populationwide. 25 Regarding long-term survival following SAVR, Malvindi et al…”

Section: Long-term Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term outcomes after transcatheter aortic valve replacement: Meta‐analysis of Kaplan−Meier‐derived data

Shimamura,

Takemoto,

Fukuhara

et al. 2023

Cathet Cardio Intervent

View full text Add to dashboard Cite

BackgroundTranscatheter aortic valve replacement (TAVR) is as an alternative treatment to surgical AVR, but the long‐term outcomes of TAVR remain unclear.AimsThis study aimed to analyze long‐term outcomes following TAVR using meta‐analysis.MethodsA literature search was performed with MEDLINE, EMBASE, Cochrane Library, Web of Science, and Google Scholar through November 2022; studies reporting clinical outcomes of TAVR with follow‐up periods of ≥8 years were included. The outcomes of interest were overall survival and/or freedom from structural valve deterioration (SVD). Surgical risk was assessed with the Society of Thoracic Surgeons (STS) predicted risk of mortality (PROM) score. A subgroup analysis was conducted for intermediate‐/high‐surgical risk patients only.ResultsEleven studies including 5458 patients were identified and analyzed. The mean age was 82.0 ± 6.5 years, and mean STS PROM score ranged from 2.9 to 10.6%. Survival rate at 5 and 10 years was 47.7% ± 1.4% and 12.1 ± 2.0%. Five studies including 1509 patients were analyzed for SVD. Freedom from SVD at 5 and 8 years was 95.5 ± 0.7% and 85.1 ± 3.1%. Similar results for survival and SVD were noted in the subgroup analysis of intermediate‐/high‐risk patients.ConclusionsFollowing TAVR, approximately 88% of patients died within 10 years, whereas 85% were free from SVD at 8 years. These date suggest that baseline patient demographic have the greatest impact on survival, and SVD does not seem to have a prognostic impact in this population. Further investigations on longer‐term outcomes of younger and lower‐risk patients are warranted.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Long-term Survivalmentioning

confidence: 99%